蒂卡格勒勒作为双RAS调节器和线粒体稳定剂:亨廷顿病的多面神经治疗策略
Ola E Mohamed1, Rabab H Sayed2, Dalaal M Abdallah3
1Postgraduate Program in Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt; Pharmacology and Toxicology Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, 12611, Egypt.
Neuropharmacology
|October 20, 2025
概括
蒂卡格勒勒在一种类似HD的老鼠模型中改善了运动功能和条纹性损伤. 这些神经保护作用涉及MAS受体激活和改善线粒体功能,提供潜在的亨廷顿病.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 亨廷顿病 (HD) 的病理生物学仍然不完全理解,已知血小板功能,ENT1和氨酸-血管新生系统 (RAS) 的改变可能会影响认知.
- 在中风和帕金森症的模型中,蒂卡格勒表现出神经保护性质,作用超出其P2Y12受体对抗性和ENT1抑制.
研究的目的:
- 在3 - 尼托普罗酸 (3-NP) 诱导的类似亨廷顿病的小鼠模型中研究蒂卡格雷勒治疗后对运动缺陷的疗效.
- 阐明基底的分子机制 蒂卡格勒洛尔的神经保护作用 在这种HD模型中,重点关注氨酸- ангиотензин系统和线粒体平衡.
主要方法:
- 患有HD症状的老鼠每天接受一周的提卡格勒罗,MAS受体 (MAS-R) 抗剂A-779或两者的组合治疗.
- 通过开放场地和旋转杆测试评估运动功能,并评估条状细胞病理学和分子变化,包括与RAS和线粒体动力学相关的基因和蛋白质表达.
主要成果:
- 提卡格雷勒治疗显著改善了体重,运动功能,并减少了由3-NP引起的条纹性损伤.
- 分子分析显示,Ticagrelor降低了林受体和林/林的调节,同时上调了MAS-R,ACE2和Ang-{1-7). 它还调节了线粒体蛋白质 (IP3R,DRP-1,PINK1,VDAC-1,Mfn-2).
- MAS-R 抗剂 A-779 部分逆转了提卡格勒罗的作用,这表明 MAS-R 激活的作用.
结论:
- 蒂卡格勒罗在类似HD的模型中显示出显著的神经治疗潜力,改善运动缺陷和神经毒性.
- 这些好处在一定程度上通过MAS-R激活,氨系统的调节和线粒体平衡的恢复来调节.
- 这些发现突出了蒂卡格勒罗作为一个有希望的候选人进一步调查亨廷顿病的治疗方法.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
814
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
814
01:24Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K